Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

61. Liraglutide in Weight Management. (Full text)

Liraglutide in Weight Management. 26510029 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1779 10.1056/NEJMc1509759 Taylor Peter N PN Baglioni Piero P eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1781-2 26510028 Female Glucagon-Like Peptide 1

2015 NEJM PubMed

62. Liraglutide in Weight Management. (Full text)

Liraglutide in Weight Management. 26510030 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1779-80 10.1056/NEJMc1509759 Mauvais-Jarvis Franck F eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1781-2 26510028 Female Glucagon-Like Peptide 1 analogs

2015 NEJM PubMed

63. Liraglutide in Weight Management. (Full text)

Liraglutide in Weight Management. 26510031 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1780 10.1056/NEJMc1509759 Gardner David M DM Murphy Andrea L AL eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):11-22 26132939 N Engl J Med. 2015 Oct 29;373(18):1781-2 26510028 Female Glucagon-Like Peptide 1

2015 NEJM PubMed

64. Liraglutide in Weight Management. (Full text)

Liraglutide in Weight Management. 26510032 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1780-1 10.1056/NEJMc1509759 Freemark Michael M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):82-3 26132945 N Engl J Med. 2015 Oct 29;373(18):1782 26516641 Female Glucagon-Like Peptide 1 analogs

2015 NEJM PubMed

65. Liraglutide in Weight Management. (Full text)

Liraglutide in Weight Management. 26510033 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Liraglutide in Weight Management. 1781 10.1056/NEJMc1509759 Paton David M DM eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 89750-14-1 Glucagon-Like Peptide 1 AIM IM N Engl J Med. 2015 Jul 2;373(1):82-3 26132945 N Engl J Med. 2015 Oct 29;373(18):1782 26516641 Female Glucagon-Like Peptide 1 analogs & derivatives

2015 NEJM PubMed

66. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study (Full text)

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study To examine the efficacy and safety of once-weekly dulaglutide monotherapy (0.75 mg) compared with placebo and once-daily liraglutide (0.9 mg) in Japanese patients with type 2 diabetes.This was a phase III, 52-week (26-week primary endpoint), randomized, double-blind, placebo-controlled (...) , open-label comparator (liraglutide) trial comparing 492 Japanese patients with type 2 diabetes (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70) who were aged ≥20 years. Patients and investigators were blinded to treatment assignment for dulaglutide and placebo but not for liraglutide. The primary objective evaluated the superiority of dulaglutide versus placebo on change from baseline in glycated haemoglobin (HbA1c) at 26 weeks. Analyses were performed on the full analysis set.At

2015 EvidenceUpdates PubMed

67. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. (Full text)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently available.To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes.Fifty-six-week randomized (2:1:1), double-blind, placebo-controlled, parallel-group (...) trial with 12-week observational off-drug follow-up period. The study was conducted at 126 sites in 9 countries between June 2011 and January 2013. Of 1361 participants assessed for eligibility, 846 were randomized. Inclusion criteria were body mass index of 27.0 or greater, age 18 years or older, taking 0 to 3 oral hypoglycemic agents (metformin, thiazolidinedione, sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.Once-daily, subcutaneous liraglutide (3.0 mg) (n

2015 JAMA PubMed

68. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. (Full text)

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had (...) a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions

2015 NEJM PubMed

69. Randomised controlled trial: Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants

Randomised controlled trial: Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants Article Text Therapeutics/Prevention Randomised controlled trial Subcutaneous

2015 Evidence-Based Medicine (Requires free registration)

70. Insulin degludec/liraglutide (Addendum to Commission A15-15)

Insulin degludec/liraglutide (Addendum to Commission A15-15) 1 Translation of addendum A15-36 Insulin degludec/Liraglutid (Addendum zum Auftrag A15-15) (Version 1.0; Status: 24 September 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 24 September 2015 1.0 Commission: A15-36 Version: Status: IQWiG Reports – Commission No. A15-36 Insulin degludec (...) /liraglutide (Addendum to Commission A15-15) 1 Addendum A15-36 Version 1.0 Insulin degludec/liraglutide (Addendum to Commission A15-15) 24 September 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (Addendum to Commission A15-15) Commissioning agency: Federal Joint Committee Commission awarded on: 8 September 2015 Internal Commission No.: A15-36 Address of publisher

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

71. Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)

Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Insulin degludec/Liraglutid (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11. November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A15-30 Insulin degludec/liraglutide (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-30 Version 1.0 Insulin degludec/liraglutide (new TI) – Benefit assessment acc. to §35a SGB V 11 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (new

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

72. Type 2 diabetes: insulin degludec/liraglutide (Xultophy)

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) T T ype 2 diabetes: insulin degludec/lir ype 2 diabetes: insulin degludec/liraglutide aglutide (Xultoph (Xultophy) y) Evidence summary Published: 3 July 2015 nice.org.uk/guidance/esnm60 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) - to-date information. Summary In people who are insulin-naïve, insulin degludec/liraglutide (Xultophy) was non-inferior to insulin degludec alone and superior to liraglutide alone for reductions in HbA1c (with a difference of 0.64% compared with liraglutide). In people previously treated with basal insulin, insulin degludec/ liraglutide was superior to insulin degludec alone for reducing HbA1c with a difference of 1.1%. The safety profile and long-term safety concerns of insulin degludec/liraglutide

2015 National Institute for Health and Clinical Excellence - Advice

73. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults

Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults. Lansdale: HAYES, Inc (...) .. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Adult; Anti-Obesity Agents; Humans; Liraglutide; Obesity; Weight Loss Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo

2015 Health Technology Assessment (HTA) Database.

74. Saxenda - liraglutide

Saxenda - liraglutide 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 11 February 2015 EMA/143005/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Saxenda International non-proprietary name: liraglutide (...) diet LDL low-density lipoprotein Lira 3.0 mg liraglutide 3.0 mg LOCF last observation carried forward Assessment report EMA/143005/2015 Page 5/91 LoQ list of questions LRQA Lloyd's Register Quality Assurance LS least square Lys lysine MAA marketing authorization application N/A not applicable NA not applicable NGSP National Glycohaemoglobin Standardization Program OAD oral antidiabetic drug OD optical density OGTT oral glucose tolerance test OR odds ratio OSA obstructive sleep apnoea PAI-1

2015 European Medicines Agency - EPARs

75. Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial (Full text)

Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Clinical studies evaluating the effects of medications on β-cell function in type 2 diabetes (T2DM) are compromised by an inability to determine the actual baseline degree of β-cell dysfunction independent of the reversible dysfunction induced by hyperglycemia (glucotoxicity). Short-term intensive insulin therapy (IIT) is a strategy for eliminating glucotoxicity before randomization (...) . This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.In this double-blind, randomized, placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 years' duration and an A1C of 6.8 ± 0.8% (51 ± 8.7 mmol/mol) completed 4 weeks of IIT before randomization to daily subcutaneous liraglutide or placebo injection, with serial assessment of β-cell function by Insulin Secretion-Sensitivity Index-2 (ISSI-2

2014 EvidenceUpdates PubMed

76. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs (Full text)

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme.Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance (...) claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models.The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81-1.49). The IR

2014 EvidenceUpdates PubMed

77. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo A network meta-analysis to compare glycaemic control in patients (...) with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo Scott DA, Boye KS, Timlin L, Clark JF, Best JH CRD summary This network meta-analysis concluded that exenatide once weekly and liraglutide (1.2mg or 1.8mg) had similar effects in improving the control of blood glucose in people with type 2 diabetes. The quality of the included trials and the applicability of the results to UK practice are uncertain

2014 DARE.

78. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. (PubMed)

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients (...) with uncontrolled type 2 diabetes.We did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013. Patients with inadequately controlled type 2 diabetes receiving metformin (≥1500 mg/day), aged 18 years or older, with glycated haemoglobin (HbA1c) 7·0% or greater (≥53 mmol/mol) and 10·0% or lower (≤86 mmol/mol), and body-mass index 45 kg/m(2) or lower were randomly assigned to receive once-weekly dulaglutide (1·5 mg) or once-daily liraglutide

2014 Lancet

79. Xultophy - insulin degludec / liraglutide

Xultophy - insulin degludec / liraglutide 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 24 July 2014 EMA/CHMP/369341/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Xultophy International non (...) -proprietary name: insulin degludec / liraglutide Procedure No. EMEA/H/C/002647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 2 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 1.2. Manufacturers 5 1.3. Steps taken for the assessment of the product 5 2. Scientific discussion 6 2.1. Introduction 6 2.2. Quality aspects 8 2.3. Non-clinical aspects 14 2.4. Clinical aspects 18 2.5. Clinical

2014 European Medicines Agency - EPARs

80. Liraglutide for obesity or overweight in patients with associated co-morbidities

Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Liraglutide for obesity

2013 Health Technology Assessment (HTA) Database.